This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. 
| INTRODUCTION
Treatment options for hemophilia have advanced dramatically over the past 5 decades, prompting changes in the choice of outcome measures to assess the value of newly proposed treatments.
Outcome measures initially used in studies of early plasma-derived and recombinant factor concentrates focused on raising factor activity (FA) levels and stopping joint bleeding. The usual design was a bioequivalence study, with a (cross-over) pharmacokinetic assessment on 12-15 patients and cases series showing that replacement therapy was allowing surgery without bleeding complications.
The success of prophylactic therapy in preventing bleeding and decreasing the progression of joint disease has established a new standard of care, progressively adopted since early childhood. As a consequence, most new products coming to the market sought an indication for prophylaxis, prompting the adoption of annualized bleeding rate (ABR) as the primary outcome. In addition, the study design evolved to include some form of comparative effectiveness to established treatment modalities, usually via randomization to different prophylaxis modalities.
In parallel, the advent of evidence-based medicine has prompted a dramatic evolution in the science of outcome assessment, including the importance of patient important outcomes (PIOs) and patient | 185
KONKLE Et aL.
reported outcomes (PROs), and their implication on patient-centered research and care.
The advent of gene therapy and coagulation mimetics, producing unprecedented results in terms of level and durability of their clotting effect, necessitates a complete reassessment of outcomes measured in hemophilia trials in light of the progress in the science of outcome measurements, to ensure appropriate assessment of the value contributed by these advanced therapies.
In this manuscript, we review strengths and limitations of outcome measures used in hemophilia and how advanced therapies impact the validity of these measurements from both a provider and patient perspective.
| BACKGROUND: AN HISTORICAL VIEW ON OUTCOME MEASURES IN HEMOPHILIA
Early studies of plasma-derived and recombinant factor replacement products were assessed for their ability to increase the FA level, [1] [2] [3] which was the primary efficacy endpoint. Other efficacy outcome measures included cessation of bleeding and surgical hemostasis. 4, 5 Safety end-points were viral safety, particularly important for plasma-derived products studied in the 1980s and 1990s, [6] [7] [8] and the development of neutralizing antibodies, termed inhibitors, which was progressively standardized as an outcome measure starting from clinical trials of recombinant FVIII (rFVIII) products in the 1990s, 9, 10 to become an important secondary outcome of all therapeutic trials.
| Factor activity level
FA reflects the genetic defect in F8 or F9 and is directly linked to the pathogenesis of the disease. 11 There is a strong correlation between endogenous factor activity levels and bleeding tendency in hemo- 
| Annualized bleeding rate
As prophylaxis has become the standard of care, and particularly with younger generations receiving prophylaxis since early childhood, 20, 21 retaining better joint health became the main goal of care. Consequently, ABR has become the primary outcome in studies of new hemophilia therapies. [22] [23] [24] Beyond aligning research and care goals, other reasons for this evolution in the choice of study outcomes were supporting the indication for prophylaxis, claims for premium value for engineered concentrates allowing more flexibility in the administration modalities while retaining full antihemorrhagic activity and safety, 25 and in general attempts to measure some form of (clinical or convenience) benefits beyond simple bioequivalence. Not all bleeds are the same: therefore while "all bleeds" is usually set as primary outcome, joint-specific ABR is often measured as a secondary outcome. Furthermore, the theoretical base for measuring ABR during prophylaxis is the concept of "break-through" bleeding, which was initially proposed to and then extrapolating to a longer period introduces a potential error due to bleeding events varying over time. 30 Methods are available to annualize bleeding rate while accounting for these fluctuations, 31 and applied by regulators in their internal analyses, but are not always applied when publishing study results. There is currently no standard approach to PIO and PROs in hemophilia trials. 53 Hemophilia-specific health quality of life tools have been developed and are used, although not in a uniform way across studies. 75, 76 These have recently been evaluated in a systematic review of their measurement properties. 75 There is lack of uniformity in populations used in validation studies and in access to tools.
| THE EVOLUTION OF OUTCOME MEASUREMENT THEORY, PATIENT-REPORTED OUTCOMES, AND PATIENT INPUT INTO RESEARCH
Available translations and cultural adaptations of measurement tools further limit applicability in international studies. 77 Multiple generic tools are also used in studies and are useful to help anchor hemophilia with other disease and with healthy populations. These may be more applicable as "normalcy" is the goal, although whether they still address the issues important to the patient will need to be addressed.
Among the many patient reported outcome instruments in the hemophilia space, the Patient Reported Outcomes, Burdens and Experiences (PROBE) project was developed by focus group methodology using both content experts and persons living with hemophilia. 78 Through this methodology outcomes of outcomes of importance and metrics to consider for measurement were determined ( Table 1 ). The PROBE questionnaire is comprised of four major sections (demographic data, general health problems, hemophilia-related health problems and health-related quality of life). The feasibility of using PROBE was assessed through a net- 
| DO ADVANCED THERAPIES REQUIRE FURTHER CHANGES ON USE OF OUTCOME MEASURES IN HEMOPHILIA?
In discussing why FA and ABR got to be selected and widely adopted in hemophilia trials, and in discussing their strength and limitations, we have unsurprisingly found the modality of treatment and the attainable goals played an important role. As advanced therapies, that is treatment moving beyond factor replacement, are expected to provide a more sustained factor activity level over time, 82 
| Coagulation mimetics
These include the bispecific antibody emicizumab and "rebalancing" drugs such as those inhibiting antithrombin or the tissue factor pathway inhibitor. 83 For these drugs there is not yet a laboratory measure that directly correlates their administration with hemostatic activity to be used as a surrogate endpoint. Bleeding events remain the primary and important endpoints. However, as these drugs may have improved efficacy when compared to standard factor concentrates, fewer patients are experiencing spontaneous bleeding episodes. Thus, other measures are needed to reflect efficacy and we would posit should be those with meaningful functional outcomes for patients and their families.
| Gene therapy
Gene therapy trials are now reporting factor activity levels in the mild hemophilia range, with a few achieving normal range, 84, 85 virtually normalizing the risk of bleeding. This would indeed apply to "otherwise" healthy subjects, which we could considered being "cured" by gene therapy. Their risk of bleeding should be as low as the normal subject. However, this might not be true for older 
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TA B L E 1 Summary of outcomes of importance and metrics to consider from PROBE a patients with establish arthropathy. For them, one may assume gene therapy would "cure" the deficiency, but not the carrying individual, as the established joint damage will still determine a limitation in function and a risk of bleeding higher than normal. In theory, for a patient with normal joints we would expect that raising the factor activity level to 0.5 IU/mL or more would completely stop bleeding. As a matter of fact, if that will be or not the case for patients with established hemophilic arthropathy is not known.
Trials on tertiary prophylaxis, that is prophylaxis begun after joint damage has occurred, have shown beneficial effect, but certainly not zeroing of bleeds. [86] [87] [88] However, trough levels in those trials were far from above 0.5 IU/mL at all times. With factor activity levels in the normal range, one would expect that even if bleeding was to happen, the trigger cause for the bleed is the preexisting local damage in the joint, and not the insufficient factor level. If a patient has such bad joints he will bleed no matter the factor level, he may benefit from gene therapy but less than others. The practical complication here is that different hemophilia populations may require different primary outcomes for gene therapy hemophilia trials, as the observed efficacy in terms of ABR (and long-term effect on joint function) of the same FA may different for patient with and without preestablished joint damage. For the foreseeable future, it is unlikely that pediatric patients with pristine joint will be enrolled in gene therapy trial, and therefore the choice of outcomes will need to adapt to feasible trials on available populations. Data from ongoing gene therapy trials seem to confirm that the expressed factor is hemostatically similarly to endogenous factor, and most of the treated patient did present zero to very few bleeds and required minimal to no additional factor replacement, but data are needed to confirm this finding on a larger scale.
Also, trialists may want to stratify patients based on established arthropathy in assessing the effect of gene therapy.
| What are the best outcome measures in trials with high and sustained clotting activity levels?
Bleeding events in patients with mild hemophilia provide insight into outcomes that may be relevant in more effective and sustained therapies, where peaks and troughs of FA are not seen. den Uijl et al assembled observational data showing that a baseline level >12%
FA would make non-traumatic bleeding very unlikely. 89 In another study, Soucie et al found more inter-individual variability, but found similar results in that individuals with levels above 15% FA had minimal joint bleeding. 90 Therefore, if gene therapy results in high and sustained hemostatic factor activity, as preliminary trials suggest, we would not expect spontaneous bleeding in patients with levels over 15% FA. On the other hand, we cannot really predict how many traumatic bleeds one would observe; first, because published data are scanty; second, because traumatic bleeds depend on level and intensity of physical activity, which may vary a lot patient to patient.
In essence, ABR or any other measure of bleeding may not be able to finely discriminate the efficacy of new therapies producing sustained high level over a short period of time and achievable samples of patients. However, ABR will remain an important "safety" out- While it is critical that we understand mechanisms responsible for observed discrepancies, and that bleeding activity be collected and correlated with activity, given issues with the ABR and the high sustained FA levels being achieved with gene therapy, it is reasonable to conclude that FA is the best primary short term surrogate endpoint.
Long-term (5-10 year time horizons) assessments of efficacy (HJHS, quality of life [QoL] ) and safety (thrombotic events, viral integration, neoplastic diseases, etc.) will tell us how good of a surrogate FA was.
Thus measuring both factor activity and bleeding events/bleeding risk and their association are important outcome measures for patient management going forward.
| Renewed need for more global patient important outcomes
Directly stemming from the above considerations is why PIOs are critical outcomes through which to assess gene therapy, beyond FA and joint function. Hopefully, gene therapy will impact the life experience of patients so deeply, that not only the number of bleeds will change, but the intrinsic "value" of a bleed will need to be redefined. With this perspective in mind, a core outcome set termed coreHEM was developed as a multi-stakeholder project, involving patients, clinicians, researchers, regulators, drug developers, and payers. 63 The frequency of bleeds, factor activity level, duration of expression, chronic pain, healthcare resource use, and mental health were identified as important core outcomes. With gene therapy there are known and unknown risks that differ from factor replacement therapy. 92 It is important that patient benefits be measured well to inform benefit/risk ratios. In addition, globally harmonized mechanisms for long term follow up and data collection are needed to assess ongoing safety of this new technology.
| GLOBAL PERSPECTIVE ON THE IMPACT OF NEW THERAPIES AND IMPLICATIONS FOR ASSESSING PATIENT OUTCOMES
Diagnosing and treating hemophilia in less developed countries remains a challenge, and only a small minority of patients has access to care. Measures to improve care of patients with hemophilia in less resourced countries are being sought. Recent studies have documented efficacy of prophylaxis, compared to episodic treatment, in children with hemophilia using doses lower than recommended for standard prophylaxis. 93, 94 However, effective dosing in all patients is needed and use of factor replacement therapy, particularly for trauma and surgical procedures, requires laboratory expertise not available in many countries. If a safe curative approach exists, this may be a better use of resources. 95 We should look to the best therapeutic approaches worldwide. This may not be repeating the drug development pathways that have been used to date in hemophilia.
However, if coagulation mimetics and gene therapy are introduced into less resourced countries, we will still need efficacy and safety measures in these populations, including patient-reported outcomes, to ensure their overall benefit in hemophilia.
| CONCLUSION
The goal of hemophilia treatment is to prevent life-threatening bleeding and long-term bleeding-related complications, thus allowing a normal life expectancy and quality of life. Advanced therapies are demonstrating improved efficacy with decreased disease burden, and the potential for cure. However, whilst we cannot claim a "cure" to last for a lifetime based on a 6 months trial data required for regulatory approval, we cannot call for life-long trials in patients with perfect joint at enrollment to document the full effect of gene therapy. Over the span of a trial, FA will be an important surrogate outcome and will serve best as the primary outcome; bleed data will remain critical secondary outcomes to appraise clinical efficacy, as well as long-term safety. Systematic collection of PIOs is critical in this process, as achieving near normal factor activity levels may change the perceived "impact" of traumatic bleeds. Fortunately, a number of tools have recently been, or are being, developed to use for this purpose. It is an exciting time in hemophilia. As new advanced therapies are introduced, we need a long-term plan to truly capture safety and efficacy in a patient relevant manner. 
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